| Ident. | Authors (with country if any) | Title |
|---|
| 000505 (2019) |
Kim Lauper [Suisse] ; Denis Mongin [Suisse] ; Deshire Alpizar-Rodriguez [Suisse] ; Catalin Codreanu [Italie] ; Florenzo Iannone [Italie] ; Eirik K. Kristianslund [Norvège] ; Tore K. Kvien [Norvège] ; Karel Pavelka [République tchèque] ; Manuel Pombo-Suarez [Espagne] ; Maria J. Santos ; Cem Gabay [Suisse] ; Axel Finckh [Suisse] ; Delphine S. Courvoisier [Suisse] | Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. |
| 000715 (2018) |
Adamah Amouzougan [France] ; Delphine Dénarié [France] ; Hubert Marotte [France] ; Xavier Roblin [France] ; Thierry Thomas [France] | Rheumatoid arthritis treated with tocilizumab in two patients with complicated chronic liver disease with portal hypertension. |
| 000A70 (2017) |
Muznay N. Khawaja [États-Unis] ; Martin J. Bergman [États-Unis] ; Jeffrey Yourish [États-Unis] ; Jinglan Pei [États-Unis] ; William Reiss [États-Unis] ; Edward Keystone [Canada] | Routine Assessment of Patient Index Data 3 and the American College of Rheumatology/European League Against Rheumatism Provisional Remission Definitions as Predictors of Radiographic Outcome in a Rheumatoid Arthritis Clinical Trial With Tocilizumab. |
| 000A73 (2017) |
Louise K. Mercer [Royaume-Uni] ; Johan Askling [Suède] ; Pauline Raaschou [Suède] ; William G. Dixon [Royaume-Uni] ; Lene Dreyer [Danemark] ; Merete Lund Hetland [Danemark] ; Anja Strangfeld [Allemagne] ; Angela Zink [Allemagne] ; Xavier Mariette [France] ; Axel Finckh [Suisse] ; Helena Canhao [Portugal] ; Florenzo Iannone [Italie] ; Jakub Zavada [République tchèque] ; Jacques Morel [France] ; Jacques-Eric Gottenberg [France] ; Kimme L. Hyrich [Royaume-Uni] ; Joachim Listing [Allemagne] | Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. |
| 000D52 (2016) |
Dinesh Khanna [États-Unis] ; Christopher P. Denton [Royaume-Uni] ; Angelika Jahreis [États-Unis] ; Jacob M. Van Laar [Pays-Bas] ; Tracy M. Frech [États-Unis] ; Marina E. Anderson [Royaume-Uni] ; Murray Baron [Canada] ; Lorinda Chung [États-Unis] ; Gerhard Fierlbeck [Allemagne] ; Santhanam Lakshminarayanan [États-Unis] ; Yannick Allanore [France] ; Janet E. Pope [Canada] ; Gabriela Riemekasten [Allemagne] ; Virginia Steen [États-Unis] ; Ulf Müller-Ladner [Allemagne] ; Robert Lafyatis [États-Unis] ; Giuseppina Stifano [États-Unis] ; Helen Spotswood [Royaume-Uni] ; Haiyin Chen-Harris [États-Unis] ; Sebastian Dziadek [Suisse] ; Alyssa Morimoto [États-Unis] ; Thierry Sornasse [États-Unis] ; Jeffrey Siegel [États-Unis] ; Daniel E. Furst [États-Unis] | Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. |
| 000D56 (2016) |
Ulrich A. Walker [Suisse] ; Veronika K. Jaeger [Suisse] ; Katerina Chatzidionysiou [Suède] ; Merete L. Hetland ; Ellen-Margrethe Hauge [Danemark] ; Karel Pavelka [République tchèque] ; Dan C. Nordström [Finlande] ; Helena Canhão ; Matija Tomši ; Ronald Van Vollenhoven [Suède] ; Cem Gabay [Suisse] | Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. |
| 000D60 (2016) |
O. Fernandez ; A. Rodriguez-Antiguedad ; J. Olascoaga ; C. Oreja-Guevara ; J M Prieto ; M M Mendibe-Bilbao ; J A Garcia-Merino ; Ll Ramio-Torrenta ; R. Ginestal ; J E Meca-Lallana ; L. Romero-Pinel ; D. Munoz ; A. Saiz ; M C Calles-Hernandez ; G. Izquierdo ; L M Villar ; P. Oliva-Nacarino ; C. Arnal-Garcia ; M. Comabella ; Ll Brieva ; R. Arroyo ; X. Montalban | Review of the novelties from the 31st ECTRIMS Congress, 2015, presented at the 8th Post-ECTRIMS meeting. |
| 000E55 (2016) |
Anders Gülfe [Suède] ; Johan K. Wallman [Suède] ; Lars Erik Kristensen [Danemark] | EuroQol-5 dimensions utility gain according to British and Swedish preference sets in rheumatoid arthritis treated with abatacept, rituximab, tocilizumab, or tumour necrosis factor inhibitors: a prospective cohort study from southern Sweden. |
| 000E68 (2016) |
Cem Gabay [Suisse] ; Myriam Riek [Suisse] ; Merete Lund Hetland [Danemark] ; Ellen-Margrethe Hauge [Danemark] ; Karel Pavelka [République tchèque] ; Matija Tomši [Slovénie] ; Helena Canhao ; Katerina Chatzidionysiou [Suède] ; Galina Lukina [Russie] ; Dan C. Nordström [Finlande] ; Elisabeth Lie [Norvège] ; Ioan Ancuta [Roumanie] ; M Victoria Hernández [Espagne] ; Piet L M C. Van Riel [Pays-Bas] ; Ronald Van Vollenhoven [Suède] ; Tore K. Kvien [Norvège] | Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study. |
| 000F85 (2015) |
Jeffrey R. Curtis [États-Unis] ; Susana Perez-Gutthann [Espagne] ; Samy Suissa [Canada] ; Pavel Napalkov [États-Unis] ; Natasha Singh [États-Unis] ; Liz Thompson [Royaume-Uni] ; Benjamin Porter-Brown [Royaume-Uni] | Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. |
| 001120 (2015) |
Maxime Dougados [France] ; Tom W J. Huizinga [Pays-Bas] ; Ernest H. Choy [Royaume-Uni] ; Clifton O. Bingham [États-Unis] ; Maher Aassi [Suisse] ; Corrado Bernasconi [Suisse] | Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. |
| 001267 (2014) |
Eugene Y. Kissin [États-Unis] | The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. |
| 001947 (2011) |
Ewa Orlewska [Pologne] ; Ioan Ancuta ; Branimir Anic ; Catalin Codrenau ; Nemanja Damjanov ; Predrag Djukic ; Ruxandra Ionescu ; Lubomir Marinchev ; Evgeny L. Nasonov ; Tonu Peets ; Sonja Praprotnik ; Rasho Rashkov ; Jana Skoupa ; Witold Tlustochowicz ; Malgorzata Tlustochowicz ; Matija Tomsic ; Tiina Veldi ; Jelena Vojinovic ; Piotr Wiland | Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries. |
| 001A65 (2009) |
| Tocilizumab: new drug. Rheumatoid arthritis: another 'mab', no therapeutic advantage. |
| 001C14 (2006) |
R N Maini [Royaume-Uni] ; P C Taylor ; J. Szechinski ; K. Pavelka ; J. Bröll ; G. Balint ; P. Emery ; F. Raemen ; J. Petersen ; J. Smolen ; D. Thomson ; T. Kishimoto | Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. |
| 001C61 (????) |
Susan Shenoi [États-Unis] ; Gerd Horneff [Allemagne] ; Michal Cidon [États-Unis] ; Athimalaipet V. Ramanan [Royaume-Uni] ; Yukiko Kimura [États-Unis] ; Pierre Quartier [France] ; Ivan Foeldvari [Allemagne] ; Andrew Zeft [États-Unis] ; Kathleen G. Lomax [États-Unis] ; Jill Gregson ; Tineke Abma [Pays-Bas] ; Sarah Campbell-Hill [États-Unis] ; Jeffrey Weiss [États-Unis] ; Dony Patel [États-Unis] ; Nina Marinsek [États-Unis] ; Nico Wulffraat [Pays-Bas] | The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. |
| 001D89 (????) |
Janice M. Reichert [États-Unis] | Marketed therapeutic antibodies compendium. |
